The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co.

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

This innovative program addresses global health initiatives and medical training in Peru with Partners in Health, known ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...